Overview

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Ixekizumab